

## CONFERENCE OBJECTIVES

InSight is seeking strategic and financial partners for the following:

1. Spinning off its biogenerics activity
2. Partnering on the development of biosimilar products for the European/US markets
3. Spinning off a cancer diagnostics company
4. Development of novel (patented) anti-cancer/inflammation monoclonal antibody
5. Investment in the company



**InSight**  
Biopharmaceuticals

## RECENT DEVELOPMENTS

Manufacturing technologies for a few blockbuster biogenerics mAbs have been commercialized in Latin America, now seeking partnership in Europe and USA

FSH manufacturing technology available for partnering

Novel anti-cancer drugs show promise in animal models

## PRODUCT AND PRODUCT CANDIDATE PIPELINE

A line of biogenerics including: FSH, different mAbs, other

Proprietary PEGylation technology

Anti-cancer NCEs (preclinical)

Anti-cancer mAbs (early-stage)

Cancer diagnostics tools (prototype)

**InSight Biopharmaceuticals Ltd.**  
POB 2128, Rabin Science Park  
Rehovot 76121, Israel  
+972 8 9463032  
[www.insight.co.il](http://www.insight.co.il)



**Dror Melamed Ph.D., MBA**  
Vice President, Operations

## Company Description

InSight Biopharmaceuticals Ltd. specializes in the discovery, development, production and commercialization of innovative biopharmaceuticals, diagnostics and biogenerics.

### *Biogenerics*

Since 1995 InSight has been a pioneer in introducing high added value biogenerics to important markets and has established strong alliances for technology transfer and product development. InSight offers a diverse line of biogenerics products, active pharmaceutical ingredients and efficient manufacturing technologies.

### *Innovative product development*

As a major part of its portfolio InSight is developing front-edge biopharmaceuticals and novel drugs. The Company maintains strong R&D programs in cancer, inflammation and additional therapeutic areas. InSight has a rich pipeline of small molecule new chemical entities and novel proteins with promising therapeutic potential, covered by extensive and strong IP.

### *Diagnostics*

Novel products for clinical use in early cancer diagnosis, staging and prognosis, based on InSight's strong IP on Heparanase are being developed.